TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8105943

Group type: EXPERIMENTAL
Intervention: 2.5 mEq/L calcium dialysate with oral calcitriol (median dose 0.25 microgram/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 3.5 mEq/L calcium dialysate without calcitriol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 2.5 mEq/L calcium dialysate with oral calcitriol
Number of subjects: 18
Study: 3310017

Group type: EXPERIMENTAL
Intervention: 20 mg sodium hyaluronate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 31504110

Group type: EXPERIMENTAL
Intervention: Amino acid (AA) supplementation (tryptophan, leucine, and glutamine) for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino acid (AA) and multiple micronutrient (MM) supplementation for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino acid (AA) supplementation
Number of subjects: 0
Study: 28087302

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study: 24448010

Group type: EXPERIMENTAL
Intervention: Modified Fox Test (MFT) with a workload of 110 W in the Study Group (n=60)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Application of modified regression norms in the Confirmatory Group (n=30)
Number of subjects: 90
Study: 24290909

Group type: EXPERIMENTAL
Intervention: Dietetic treatment
Number of subjects: 146
Study: 21556830

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei treatment for 3 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no probiotic treatment)
Number of subjects: 35
Study: 19236785

Group type: EXPERIMENTAL
Intervention: recombinant human interleukin 11 (rhIL‐11)
Number of subjects: 20

Group type: COMPARATOR
Intervention: supporting treatment
Number of subjects: 20
Study: 18001447

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 864

Group type: COMPARATOR
Intervention: Intramuscular methylergometrine
Number of subjects: 864
Study: 15021279

Group type: EXPERIMENTAL
Intervention: Buprenorphine-soaked absorbable gelatin sponge (0.3 mg buprenorphine diluted to 5 mL with normal saline)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Absorbable gelatin sponge soaked with 5 mL normal saline (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Buprenorphine-soaked absorbable gelatin sponge
Number of subjects: 60
Study: 12492609

Group type: EXPERIMENTAL
Intervention: Intravenous urotensin II infusion at 300 pmol min‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous urotensin II infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 9667477

Group type: EXPERIMENTAL
Intervention: Morning brushing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Evening brushing
Number of subjects: 30
Study: 7662780

Group type: EXPERIMENTAL
Intervention: Continuous mass polyglyconate (Maxon) double suture with loop
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Continuous mass polyglactin 910 (Vicryl)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Interrupted polyglactin 910 (Vicryl)
Number of subjects: 599

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 599
Study: 2516838

Group type: EXPERIMENTAL
Intervention: Aircast pneumatic air stirrup
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard below‐knee walking cast
Number of subjects: 40
Study: 785608

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Aspirin-Placebo
Number of subjects: 7
Study: 6988115

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 30089762

Group type: EXPERIMENTAL
Intervention: Del Nido solution (DNS)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Intermittent warm blood cardioplegia (IWBC)
Number of subjects: 297
Study: 28193369

Group type: EXPERIMENTAL
Intervention: Multimodal Intervention (MI)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Traditional Intervention (TI)
Number of subjects: 302
Study: 26214684

Group type: EXPERIMENTAL
Intervention: Agricultural and finance intervention (human-powered water pump, microfinance loan, education in sustainable farming and financial management)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Agricultural and finance intervention
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study: 23687089

Group type: EXPERIMENTAL
Intervention: Early immature gene expression signature
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Absence of bi-allelic TCRG deletion
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CD13 surface expression
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Heterozygous deletions of the short arm of chromosome 17
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Mutations in IDH1/IDH2 and DNMT3A genes
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Expression of CD8 or CD62L
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Homozygous deletion of CDKN2A/CDKN2B
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: NOTCH1 and/or FBXW7 mutations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Mutations or deletions in the BCL11B tumor suppressor gene
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CD13 expression and homozygous CDKN2A/CDKN2B deletions
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Mutations in IDH1/IDH2 and DNMT3A
Number of subjects: 53
Study: 21221988

Group type: EXPERIMENTAL
Intervention: Individuals with Down syndrome (DS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Individuals without Down syndrome (non-DS)
Number of subjects: 40
Study: 19661687

Group type: EXPERIMENTAL
Intervention: 15 ml of vinegar (750 mg AcOH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 ml of vinegar (1,500 mg AcOH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 ml of vinegar (0 mg AcOH, placebo)
Number of subjects: 0
Study: 17370665

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with Atrisorb membrane
Number of subjects: 31

Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 31
Study: 15220300

Group type: EXPERIMENTAL
Intervention: Physical training (40 min of stationary cycling, 4 times/week for 8 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (sedentary patients, n = 15)
Number of subjects: 16
Study: 11888224

Group type: EXPERIMENTAL
Intervention: Venlafaxine (18.75 mg daily, increased by one tablet at 1 week intervals)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Venlafaxine and Placebo
Number of subjects: 13
Study: 9863332

Group type: EXPERIMENTAL
Intervention: Endocervical application of 0.5 mg Dinoprostone (Group I)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intravenous application of Syntocinon (Group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both methods of labor induction (Group I and Group II)
Number of subjects: 90
Study: 7675391

Group type: EXPERIMENTAL
Intervention: Prophylactic strategies (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin (anticoagulant of choice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consensus recommendations (not specified)
Number of subjects: 0
Study: 2116057

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (200 micrograms, as an i.v. bolus)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control saline (in isovolumic amount)
Number of subjects: 30
Study: 146331

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus heparin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 49
Study: 29868722

Group type: EXPERIMENTAL
Intervention: Recent overnight travel
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Not using an insecticide‐treated net during travel
Number of subjects: 906

Group type: EXPERIMENTAL
Intervention: Young age (children)
Number of subjects: 906
Study: 28004188

Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg/6 h IV infusion for 3 days)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg IV infusion followed by 5 mg/kg/day for 2 days)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg/12 h IV infusion for three doses)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study: 26342584

Group type: EXPERIMENTAL
Intervention: Double List Experiment (List A and List B)
Number of subjects: 3219
Study: 24308191

Group type: COMPARATOR
Intervention: Cervical paravertebral block (control) group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture plus cervical paravertebral block (acupuncture) group
Number of subjects: 60
Study: 22018631

Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy for 5 years
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Tamoxifen monotherapy for 5 years
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Letrozole followed by tamoxifen (2 years letrozole, 3 years tamoxifen)
Number of subjects: 8010

Group type: COMPARATOR
Intervention: Tamoxifen followed by letrozole (2 years tamoxifen, 3 years letrozole)
Number of subjects: 8010
Study: 19886855

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg to 300/25 mg
Number of subjects: 695

Group type: COMPARATOR
Intervention: Irbesartan 150 mg to 300 mg
Number of subjects: 695
Study: 16143443

Group type: EXPERIMENTAL
Intervention: Peppermint
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 21
Study: 15378542

Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Client-centered counseling
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Testing negative for BRCA1/2 mutation
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Testing positive for BRCA1/2 mutation
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-testers
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Personal history of cancer
Number of subjects: 212
Study: 12197793

Group type: EXPERIMENTAL
Intervention: Kaiser Permanente Colorado Asthma Care Management Program
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 298
Study: 9768826

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DEX) administered 30 minutes before daunorubicin (DNR) 45 mg/m2 or mitoxantrone (MTX) 10 mg/m2, in doses 8-13 times higher for DNR or 30-60 times higher for MTX, with a treatment cycle including 10 high doses (2,000 mg/m2/12 hr) of cytosine arabinoside plus two doses of DNR or MTX on days 4 and 5.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DEX) as a cardioprotective agent during chemotherapy.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Delayed administration of DEX after cumulative doses of DNR 500 mg/m2.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen including DEX, DNR, MTX, and cytosine arabinoside.
Number of subjects: 8
Study: 8576413

Group type: EXPERIMENTAL
Intervention: Removable speech appliance developed by Clark, Schwarz, and Blakeley (1993)
Number of subjects: 0
Study: 2667633

Group type: COMPARATOR
Intervention: Propantheline bromide
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Oxybutinin hydrochloride and Propantheline bromide
Number of subjects: 23
Study: 408860

Group type: EXPERIMENTAL
Intervention: L-tryptophan treatment
Number of subjects: 0
Study: 30901920

Group type: EXPERIMENTAL
Intervention: 3 mg nicotine of TC (3TC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3 mg nicotine of EC (3EC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control 0 mg nicotine of EC (C)
Number of subjects: 24
Study: 30400586

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamins C, E, D, zinc, beta-carotene, lutein, zeaxanthin, omega-3 fatty acids)
Number of subjects: 300000000

Group type: EXPERIMENTAL
Intervention: Dietary habits (high-fat and high-glucose or -fructose diets)
Number of subjects: 300000000
Study: 26679253

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study: 25332492

Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 22301466

Group type: EXPERIMENTAL
Intervention: 24-week pegylated interferon plus ribavirin therapy
Number of subjects: 662
Study: 19490745

Group type: EXPERIMENTAL
Intervention: Psychotherapy (high-quality studies)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Psychotherapy (lower-quality studies)
Number of subjects: 115
Study: 16763372

Group type: EXPERIMENTAL
Intervention: Elevated serum total homocysteine levels
Number of subjects: 3090

Group type: EXPERIMENTAL
Intervention: Each 5 mumol/l increment in homocysteine levels
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Control group (matched for age and gender)
Number of subjects: 3090
Study: 16303792

Group type: EXPERIMENTAL
Intervention: Docetaxel (66 mg/m² Day 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Docetaxel (33 mg/m² Days 1 and 8)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Arm A (66 mg/m² Day 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Arm B (33 mg/m² Days 1 and 8)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Response to front-line chemotherapy
Number of subjects: 50
Study: 12010910

Group type: EXPERIMENTAL
Intervention: POTS patients with high venous pressure (P(v)>20 mm Hg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: POTS patients with normal venous pressure
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 10051277

Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microgram/puff)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 18
Study: 10155119

Group type: EXPERIMENTAL
Intervention: Perfusion balloon as a primary dilation device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion balloon as a primary device
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary perfusion angioplasty with stent bailout when needed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion balloon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion angioplasty as a primary treatment strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion balloon as an initial device
Number of subjects: 0
Study: 2288830

Group type: EXPERIMENTAL
Intervention: 50 ml cream (20 g fat) preload with placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 ml cream (20 g fat) preload with 10 mg cisapride
Number of subjects: 12

Group type: COMPARATOR
Intervention: 50 ml water preload with placebo
Number of subjects: 12
Study: 6966082

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 20
Study: 31864932

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 100
Study: 30975055

Group type: EXPERIMENTAL
Intervention: Microcurrent Electrical Stimulation (MES)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard Wound Care (Control)
Number of subjects: 45
Study: 27764906

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 IV on D1 (D)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Docetaxel 60 mg/m2 IV plus cisplatin 60 mg/m² IV on D1 (DC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 IV D1 plus oral S-1 30 mg/m2 twice a day on D1-14 (DS)
Number of subjects: 72
Study: 27488051

Group type: EXPERIMENTAL
Intervention: L-citrulline and metformin therapy for 26 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: L-citrulline and metformin therapy
Number of subjects: 40
Study: 25056431

Group type: EXPERIMENTAL
Intervention: Web-based shared-care software
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Software implementation and performance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GP users' evaluation via questionnaire
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Software usage collected via GP questionnaire
Number of subjects: 30
Study: 21555171

Group type: EXPERIMENTAL
Intervention: Submucous tramadol 50mg (1mL of saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Submucous placebo (1mL of saline)
Number of subjects: 20
Study: 19614635

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.1 mmol/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.3 mmol/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gadobutrol 0.5 mmol/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17442681

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1000 mg) + Caffeine (130 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Caffeine (130 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15896835

Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for smoking cessation
Number of subjects: 5407

Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for dietary improvement
Number of subjects: 5407

Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for sun exposure reduction
Number of subjects: 5407

Group type: EXPERIMENTAL
Intervention: Stage-based expert systems intervention for regular mammography adherence
Number of subjects: 5407
Study: 11817529

Group type: EXPERIMENTAL
Intervention: Heparin-coated (HC) VVBP equipment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncoated (NC) VVBP circuits
Number of subjects: 20
Study: 9585294

Group type: EXPERIMENTAL
Intervention: Lornoxicam (Xefo; administered i.v. via PCA for up to 24 h)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Morphine (administered i.v. via PCA for up to 24 h)
Number of subjects: 96
Study: 7543580

Group type: EXPERIMENTAL
Intervention: Project CHILD program (Community Health Initiatives Against Learning Difficulties)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoeducational and medical screenings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental empowerment initiatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based and comprehensive child health care
Number of subjects: 0
Study: 1639833

Group type: EXPERIMENTAL
Intervention: Fast lifting condition
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Accelerated lifting condition
Number of subjects: 5

Group type: COMPARATOR
Intervention: Slow lifting condition
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Fast lowering condition
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Slow lowering condition
Number of subjects: 5

Group type: COMPARATOR
Intervention: Maximal values from isokinetic dynamometry
Number of subjects: 5
Study: 6383447

Group type: EXPERIMENTAL
Intervention: Diazepam plus pethidine, reversed with naloxone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam alone
Number of subjects: 100
Study: 30274699

Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced thermo-chemotherapy effect (RITE) with 40mg mitomycin-C at 42±2°C for 60 minutes
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced thermo-chemotherapy effect (RITE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control (institutional standard second-line therapy)
Number of subjects: 104
Study: 29173218

Group type: EXPERIMENTAL
Intervention: Multi-strategy implementation intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 45
Study: 26970266

Group type: EXPERIMENTAL
Intervention: Armodafinil (150-200 mg/day)
Number of subjects: 867
Study: 24887579

Group type: EXPERIMENTAL
Intervention: Seattle Heart Failure Model (SHFM) score increase by 1 unit
Number of subjects: 2331
Study: 22976237

Group type: EXPERIMENTAL
Intervention: Use of a computerized language lateralization index (CLI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No use of a computerized language lateralization index (CLI)
Number of subjects: 22
Study: 20571015

Group type: EXPERIMENTAL
Intervention: Folic acid plus vitamin B12
Number of subjects: 12064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12064
Study: 18465241

Group type: EXPERIMENTAL
Intervention: Ingesting 500 ml of polyethylene glycol (PEG) starting 30 min after swallowing the capsule
Number of subjects: 59

Group type: COMPARATOR
Intervention: No preparation (control group A)
Number of subjects: 59
Study: 16371776

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 0.05% (tCsA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (Refresh Plus preservative-free artificial tears)
Number of subjects: 33
Study: 14645769

Group type: EXPERIMENTAL
Intervention: Telephone disease management (TDM) program
Number of subjects: 97

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 97
Study: 10999974

Group type: EXPERIMENTAL
Intervention: Moderate increases in alcohol consumption (>1 to <6 drinks per week) among men initially consuming 1 drink per week or less (n=7360)
Number of subjects: 18455

Group type: EXPERIMENTAL
Intervention: Moderate increases in alcohol consumption among men initially consuming greater than 1 to 6 drinks per week (n=6612)
Number of subjects: 18455

Group type: EXPERIMENTAL
Intervention: Increased alcohol intake among men initially consuming 1 drink per day or more (n=4483)
Number of subjects: 18455
Study: 9004052

Group type: EXPERIMENTAL
Intervention: Doxepin (mean daily dosage at 6 weeks 169 +/- 42 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine (mean daily dosage at 6 weeks 37 +/- 18 mg)
Number of subjects: 40
Study: 8285374

Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg (plain tablet)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 8